Arrayus Technologies touts clinical trial for locally advanced breast cancer

AuntMinnie.com staff writers

Dec 5, 2024

Focused ultrasound developer Arrayus Technologies is promoting the completion of focused ultrasound treatment for breast cancer at Sunnybrook Health Sciences Centre in Toronto by 30 patients participating in a phase I prospective clinical trial using the company’s focused ultrasound platform.

The trial, led by Gregory Czarnota, MD, is evaluating the safety and potential of the Arrayus device to enhance tumor response to external beam radiation therapy. MR-guided focused ultrasound is delivered with microbubble therapy to enhance the therapeutic effects of radiation in patients with locally advanced breast cancer.

Arrayus’ focused ultrasound system uses proprietary technology and has a fully phased array, intuitive treatment planning tools, and real-time therapy monitoring. Its features enable clinicians to tailor treatments based on individual disease characteristics, the company advises.

The system received clearance from Health Canada in October 2024 for its use to ablate uterine fibroid tissue.

(A) Free-response receiver operating characteristic (FROC) curve for DBT-DINO and DINOv2 (Meta AI) on the detection task. DINOv2 achieved higher sensitivity than DBT-DINO across most false-positive thresholds. (B) Detection rates of DBT-DINO and DINOv2 for lesions that were ultimately found to be benign (n = 70) and lesions that were found to be cancerous (n = 66). Error bars represent 95% CIs estimated via patient-level bootstrapping with 1000 repetitions. Both models showed similar detection rates for cancerous lesions, whereas DINOv2 detected more benign lesions than DBT-DINO. (C) Example bounding box predictions for DBT-DINO and DINOv2 on the detection test set. Each image is a single two-dimensional section from a three-dimensional digital breast tomosynthesis volume; the first column shows a mediolateral oblique view, and the second and third columns show craniocaudal views. Both models struggled to detect very small lesions, such as the 3-mm-diameter lesion shown in the first column. FP = false positive.

DBT-based foundational model classifies breast density

August 4, 2026

Research Money 400

Medara nets $400,000 NCI grant for AI breast cancer risk platform

August 4, 2026

Minnie Cast Thumbnail (17)

Women's Imaging MinnieCast, Episode 14: GLP-1s and breast cancer risk

July 31, 2026

RadSite publishes clinical coverage guideline for breast CBCT imaging

July 30, 2026

DBT-based foundational model classifies breast density

By Amerigo Allegretto

DBT-DINO showed strong performance in classifying breast density from DBT images.

August 4, 2026

(A) Free-response receiver operating characteristic (FROC) curve for DBT-DINO and DINOv2 (Meta AI) on the detection task. DINOv2 achieved higher sensitivity than DBT-DINO across most false-positive thresholds. (B) Detection rates of DBT-DINO and DINOv2 for lesions that were ultimately found to be benign (n = 70) and lesions that were found to be cancerous (n = 66). Error bars represent 95% CIs estimated via patient-level bootstrapping with 1000 repetitions. Both models showed similar detection rates for cancerous lesions, whereas DINOv2 detected more benign lesions than DBT-DINO. (C) Example bounding box predictions for DBT-DINO and DINOv2 on the detection test set. Each image is a single two-dimensional section from a three-dimensional digital breast tomosynthesis volume; the first column shows a mediolateral oblique view, and the second and third columns show craniocaudal views. Both models struggled to detect very small lesions, such as the 3-mm-diameter lesion shown in the first column. FP = false positive.

Medara nets $400,000 NCI grant for AI breast cancer risk platform

By AuntMinnie.com staff writers

The platform combines longitudinal mammographic imaging with clinical risk factors to predict short-term breast cancer risk.

August 4, 2026

Research Money 400

Women's Imaging MinnieCast, Episode 14: GLP-1s and breast cancer risk

By Amerigo Allegretto

Elizabeth McDonald, MD, shares results from her team's study on how GLP-1s may have beneficial effects on breast cancer risk.

July 31, 2026

Minnie Cast Thumbnail (17)

RadSite publishes clinical coverage guideline for breast CBCT imaging

By AuntMinnie.com staff writers

The guide outlines how breast CBCT should be used when conventional imaging approaches are inconclusive or inaccessible.

July 30, 2026

CEM finds breast cancer at baseline, incidence screening

By Amerigo Allegretto

Incidence screening with CEM maintains high performance and may offer more benefits over baseline CEM screening.

July 28, 2026

Images in a 70-year-old asymptomatic woman with a prior excisional biopsy in the left breast yielding lobular carcinoma in situ 3 years earlier. Screening contrast-enhanced mammography (CEM) was performed, which was considered a prevalence screen as the woman had no prior breast MRI in the past 3 years and no prior CEM. (A) Low-energy (26–30 kVp) mediolateral oblique (MLO) and (B) craniocaudal (CC) views show surgical clips but no abnormality. (C) Recombined MLO and (D) CC images show an enhancing mass in the medial left breast (arrows). Biopsy revealed invasive lobular carcinoma. Size was 0.2 cm; tumor grade II/III; negative lymph nodes; and estrogen receptor–positive, progesterone receptor–positive, and human epidermal growth factor receptor 2–negative.

QT Imaging nets Israeli registration for Breast Acoustic CT scanner

By AuntMinnie.com staff writers

The registration authorizes commercialization of the company's Breast Acoustic CT Scanner in Israel through early 2028.

July 28, 2026

Breast Self Exam2 400

Uterine fibroid assessment differs by imaging technique

By Amerigo Allegretto

MRI and ultrasound differ in mapping uterine fibroids in women undergoing laparoscopic-assisted robotic myomectomy.

July 27, 2026

Uterus Pelvic 400 (1)

Women's Imaging MinnieCast, Episode 13: Partial breast irradiation in the spotlight

By Amerigo Allegretto

Two committee members for ASTRO's PBI guidelines share insights about this breast cancer treatment option.

July 17, 2026

Minnie Cast Thumbnail (15)

Incorrect AI suggestions influence reader performance on mammography

By Amerigo Allegretto

The biggest impact on reader performance stemmed from false-negative AI suggestions.

July 14, 2026

A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.

Breast cancer screening higher among civically engaged women

By Amerigo Allegretto

Women who voted, attended a public meeting, or volunteered are more likely to get their breast cancer screening.

July 14, 2026

Mammogram Calendar 400

CEM on par with MRI for breast cancer diagnosis, local staging

By Amerigo Allegretto

CEM alone in a prospective study achieved perfect sensitivity and negative predictive value in diagnosing breast cancer.

July 10, 2026

MRI false positive for additional disease, (top to bottom): A. Index lesion—grade 2 invasive ductal carcinoma; B. MRI lesion two, upper inner quadrant: Stromal sclerosis and columnar cell change; C. MRI lesion three, upper outer quadrant: No ultrasound correlate, no malignancy on follow-up; D. CEM marked background parenchymal enhancement with a unifocal retroareolar lesion demonstrating wash-out on delayed MLO. Images are republished under a Creative Commons license (CC BY 4.0).

PreludeDx, Learn Look Locate launch DCIS patient education resource

By AuntMinnie.com staff writers

The patient-centered guide will cover various aspects of DCIS, including recurrence risk and radiation therapy decision-making.

July 9, 2026

Page 1 of 710